Jaguar Health (NASDAQ:JAGX) Research Coverage Started at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Jaguar Health (NASDAQ:JAGX) in a report issued on Wednesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Jaguar Health Trading Down 6.0 %

JAGX stock opened at $0.30 on Wednesday. Jaguar Health has a twelve month low of $0.05 and a twelve month high of $1.22. The company has a current ratio of 2.00, a quick ratio of 1.34 and a debt-to-equity ratio of 6.33. The firm’s fifty day simple moving average is $0.13 and its two-hundred day simple moving average is $0.17.

About Jaguar Health

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.